NeuroVigil Inc. and Roche Launch Personalized Neurodiagnostics Initiative for Enabling Preventive Treatment of CNS Disorders

SAN DIEGO--(BUSINESS WIRE)--Today, leading California Neurotechnology company NeuroVigil and Swiss Pharma giant Roche announced an agreement regarding a major innovation in collecting and analyzing data from clinical trials. NeuroVigil will provide Roche with its iBrain devices and accompanying software analysis services to help speed up Roche’s drug development for various CNS disorders. NeuroVigil’s advanced portable, noninvasive iBrainTM devices will be used to monitor neural activity in outpatient clinical trials. NeuroVigil will analyze the resulting data on a patient-by-patient basis using the NeuroVigil proprietary software algorithms and brain derived biomarker libraries to further characterize the compounds from Roche. These services will enable Roche to detect subtle individual changes in brain activity at very low drug dosages, often before the onset of cognitive symptoms and adverse effects.

Back to news